Japanese drugs giant Eisai is pulling the use of human genetics deeper into its drug development process via a new deal with UK-based genome analytics firm Genomics.

The companies have signed a collaborative agreement under which Eisai will use Genomics’ statistical analyses of large-scale, multi-phenotype, genetic association data to underpin various stages of the drug discovery process, such as target selection and validation and choosing the right indication.

Eisai's new Integrated Human Genomics Research Unit will hook up with Genomics to use genetic information to speed up the discovery and development of “impactful new medicines”, the Tokyo-based firm said.

According to Professor Peter Donnelly, a director and founder of Genomics, the work “will demonstrate the real value that powerful analyses of large genomic databases can add to drug development pipelines”.